Sox2 promotes tamoxifen resistance in breast cancer cells.

Piva M, Domenici G, Iriondo O, Rábano M, Simões BM, Comaills V, Barredo I, López-Ruiz JA, Zabalza I, Kypta R, Vivanco Md. · 2014

Read Sox2 promotes tamoxifen resistance in breast cancer cells. by Piva M, Domenici G, Iriondo O, Rábano M, Simões BM, Comaills V, Barredo I, López-Ruiz JA, Zabalza I, Kypta R, Vivanco Md. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3936493.txt.

Introduction

Marco Piva and colleagues show in EMBO Molecular Medicine in 2014 that a stem-cell factor helps breast cancer resist the drug tamoxifen. Resistance to hormone therapy is a standing problem in breast cancer care, and cancer stem-like cells are suspected drivers. The team compared tamoxifen-resistant breast cancer cells with sensitive ones and looked for what the resistant cells carried more of.

Resistant cells were rich in stem-like cells with high levels of Sox2, a gene that helps stem cells stay stem-like. Silencing Sox2 shrank that population and restored drug sensitivity, while adding Sox2 to sensitive cells made them resistant in dishes and in animals. Sox2 worked partly by switching on the Wnt signaling pathway; blocking Wnt re-sensitized the cells. Patient tumors that had failed hormone therapy also showed higher Sox2.

Catalog record

CREATORPiva M, Domenici G, Iriondo O, Rábano M, Simões BM, Comaills V, Barredo I, López-Ruiz JA, Zabalza I, Kypta R, Vivanco Md.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE63 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3936493

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Sox2 promotes tamoxifen resistance in breast cancer cells By Marco Piva, Giacomo Domenici, Oihana Iriondo, Miriam Rábano, Bruno M Simões, Valentine Comaills, Inmaculada Barredo, Jose A López-Ruiz, Ignacio Zabalza, Robert Kypta, Maria d M Vivanco Published in: EMBO Molecular Medicine DOI: 10.1002/emmm.201303411 ABSTRACT Abstract Development of resistance to therapy continues to be a serious clinical problem in breast cancer management. Cancer stem/progenitor cells have been shown to play roles in resistance to chemo- and radiotherapy. Here, we examined their role in the development of resistance to the oestrogen receptor antagonist tamoxifen. Tamoxifen-resistant cells were enriched for stem/progenitors and expressed high levels of the stem cell marker Sox2. Silencing of the SOX2 gene reduced the size of the stem/progenitor cell population and restored sensitivity to tamoxifen. Conversely, ectopic expression of Sox2 reduced tamoxifen sensitivity in vitro and in vivo. Gene expression profiling revealed activation of the Wnt signalling pathway in Sox2-expressing cells, and inhibition of Wnt signalling sensitized resistant cells to tamoxifen. Examination of patient tumours indicated that Sox2 levels are higher in patients after endocrine therapy failure, and also in the primary tumours of these patients, compared to those of responders. Together, these results suggest that development of tamoxifen resistance is driven by Sox2-dependent activation of Wnt signalling in cancer stem/progenitor cells. Keywords: breast cancer, Sox2, stem cells, tamoxifen resistance, wnt signalling INTRODUCTION Breast cancer is the most common female cancer and approximately 70–75% of cases express oestrogen receptor alpha (ERα). Tamoxifen, an oestrogen antagonist in the breast, has been the standard endocrine therapy for women with ERα-positive breast cancer for many years and remains so for premenopausal and a substantial number of postmenopausal patients (Jordan & O'Malley, 2007). In many cases, however, resistance to endocrine therapy develops, although ERα expression is maintained in most tumours that acquire resistance (Ali & Coombes, 2002). The potential mechanisms underlying this resistance to endocrine therapy involve ER-coregulatory proteins and cross-talk between the ER pathway and other growth-factor signalling networks (Osborne et al, 2005). A growing body of evidence is accumulating supporting the hypothesis that cancer stem cells, or tumour-initiating cells, drive and maintain many types of human malignancies (Diehn et al, 2009). The cancer stem cell hypothesis has shed new light on the development of resistance to therapy, proposing that there exists a pool of malignant cells with stem/progenitor cell properties and increased capacity to resist common chemotherapeutic treatments, compared to their more differentiated non-tumourigenic counterparts, and therefore responsible for tumour recurrence after treatment (Reya et al, 2001). Breast cells with the phenotype CD44+CD24−/lowlineage− isolated from metastatic pleural effusions by fluorescence activated cell sorting (FACS) are highly enriched for tumour-initiating cells (Al-Hajj et al, 2003). Importantly, the CD44+CD24−/low cell population increases in size after chemotherapy and is associated with enhanced ability to form mammospheres, suggesting that these cells are more resistant to treatment (Li et al, 2008). In addition, normal and cancer breast epithelial cells with increased aldehyde dehydrogenase activity (ALDH) show stem/progenitor cell propertiesin vitro and in vivo and are associated with poor clinical outcome (Ginestier et al, 2007). Finally, poorly differentiated breast tumours contain a higher proportion of cancer stem cells than well-differentiated cancers (Pece et al, 2010). Previously, we observed that oestrogen reduces the pool of breast stem cells while tamoxifen has the opposite effect (Simoes et al, 2011). The relevance of the increase in the proportion of cancer stem cells upon tamoxifen treatment is intriguing in the context of the development of tamoxifen resistance in breast cancer patients. Furthermore, normal and cancer stem cells share phenotypes that may reflect the activity of common signalling pathways, such as high expression of NANOG, OCT4 and SOX2, which is reduced by oestrogen (Simoes et al, 2011). In breast tumours, an embryonic stem cell (ES)-like signature characterized by activation of targets of Nanog, Oct4 and Sox2 is associated with high-grade ER-negative tumours and with aggressive tumour behaviour (Ben-Porath et al, 2008), supporting the possibility that ES genes contribute to the stem cell-like phenotype found in many tumours. Here, we present evidence that Sox2, a transcription factor that is key in maintaining pluripotent properties of stem cells, is a crucial player in the development of resistance to tamoxifen in ER-positive breast cancer cells. Sox2 overexpression increases the proportion of breast cancer stem/progenitor cells by activating the Wnt signalling pathway, thereby rendering the cells insensitive to the growth inhibitory effects of tamoxifen. These findings, together with the observation that Sox2 levels are elevated in the primary tumours of patients that do not respond to endocrine therapy, suggest that Sox2 could represent a prognostic factor for development of resistance to tamoxifen and that Wnt signalling may be an attractive therapeutic target in these patients. RESULTS Increased tumourigenicity during the development of tamoxifen resistance compromises ER transcriptional activity The development of tamoxifen resistance in breast cancer cells was used as a model for the acquisition of resistance to oestrogen antagonists that occurs in breast cancer patients. The oestrogen sensitive MCF-7 breast cancer cell line was cultured in the presence of tamoxifen or, in parallel, with the carrier ethanol. Initially, cell growth rates were very much reduced in the presence of tamoxifen, but eventually cells adapted to the new environment leading to two new sub-lines: MCF-7TamR (resistant to tamoxifen treatment) and control MCF-7c cells. The control MCF-7c cells are indistinguishable from the parental MCF-7 cells with respect to their proliferation capacity in normal growth medium, which is also similar to the MCF-7TamR cells (Fig 1A). As expected, control cell proliferation was reduced by tamoxifen, while MCF-7TamR cells grew at a similar rate, independently of the presence of tamoxifen (Fig 1B). Subcutaneous transplantation of MCF-7TamR cells to athymic mice led to larger and faster growing tumours compared to the parental MCF-7 cells, indicating their increased tumourigenic potential (Fig 1C). Immunoblot analysis revealed that MCF-7TamR cells remain ERα positive (ERα will be referred to as ER), like parental MCF-7 cells (Fig 1D). Despite constant levels of ER expression, ER transcriptional activity was lower in MCF-7TamR cells than in control cells in the context of a consensus oestrogen response element (Fig 1E). In addition, expression of the progesterone receptor (PR), a well-known ER target gene, was strongly reduced in MCF-7TamR cells (Fig 1F). These results indicate that MCF-7TamR cells are more tumourigenic than parental MCF-7 cells and, although they express comparable levels of ER, its transcriptional activity is reduced in MCF-7TamR cells. [Figure: Characterization of MCF-7TamR cells.A Proliferation assay of MCF-7 (wt), MCF-7c (control) and MCF-7TamR (tamoxifen resistant) cells (n = 3).B Proliferation assay of MCF-7c and MCF-7TamR cells treated with ethanol (OH) or 5 × 10−7 M tamoxifen (Tam) (n = 3).C Tumour growth curve of MCF-7c and MCF-7TamR cells implanted s.c. in athymic mice in the presence of an exogenous slow release, oestrogen implant (n = 5 mice/group).D Western blot analysis of ERα expression in MCF-7c (c) and MCF-7TamR cells.E MCF-7 (grey bars), MCF-7c (white bars) and MCF-7TamR (black bars) cells were transfected with a reporter plasmid containing three copies of a consensus ERE driving a luciferase reporter in the presence of the carrier ethanol (OH) or 5 × 10−7 M tamoxifen (Tam) or 10−8 M oestrogen (E2). In all transfections, β-galactosidase activity was used to control for transfection

Read the complete text